Business
miRagen to Host a Key Opinion Leader Call on Idiopathic Pulmonary Fibrosis on Tuesday, June 23rd
miRagen to announce encouraging new preclinical safety and efficacy data for MRG-229 in IPF on June 22nd; and provide an update on the development program
About this update from Viridian Therapeutics, Inc.
[{"type":"text","content":"miRagen to announce encouraging new preclinical safety and efficacy data for MRG-229 in IPF on June 22nd; and provide an update on the development program during the KOL call\nBOULDER, Colo., June 16, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced it is scheduled to host a key opinion leaders (KOL) call regarding idiopathic pulmonary fibrosis (IPF) on Tuesday, June 23rd at 11 a.m. Eastern Time. The Company will also discuss encouraging new preclinical safety and efficacy data for its MRG-229 being developed for the treatment of IPF during the call.\n The call will feature a discussion by KOLs Fernando J. Martinez, MD, Weill Cornell Medicine, Teresa Barnes, Coalition for Pulmonary Fibrosis, and Naftali Kaminski, MD, Yale School of Medicine. The KOLs will discuss the current and increasing unmet medical needs in treating patients with IPF. Dr. Martinez, Dr. Kaminski, and Ms. Barnes will be available to answer questions at the conclusion of the call. Rusty Montgomery, PhD, Director of Research at miRagen, will also discuss the development of MRG-229 in IPF, including the presentation of new preclinical safety and efficacy data. MRG-229 is a second-generation mimic of miR-29, a microRNA that is found at abnormally low levels in a number of pathologic fibrotic conditions, including idiopathic pulmonary fibrosis (IPF). miR-29 is believed to play a role in the regulation of certain processes that contribute to fibrosis, including the initiation and maintenance of fibrosis through transforming growth factor beta, or TGF-β, signaling and the deposition of the components that make up fibrotic tissue, including collagen and extracellular matrix proteins. The company believes that increasing the levels of miR-29 by administration of MRG-229 could be beneficial in the treatment of patients who suffer from IPF. This program was recently awarded additional funds from an NIH/NHLBI CADET grant and Yale University. Conference Call Details: Date:Tuesday, June 23rdTime:11 a.m. Eastern TimeDomestic:877-407-0789International:201-689-8562Conference ID:13705048Webcast:To enter webcast (Click Here) or visit the Events section of miRagen’s website: www.investors.miragen.com/events Dr. Martinez is the Chief of...